Clinical utility of oral valcyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy

Bone Marrow Transplantation

Volumn 31, Issue 1, 2003, Pages 51-55

  Eisen, D ^a   Essell, J ^b   Broun, E R ^b   Sigmund, D ^b   DeVoe, M ^b  

^a Dermatology Research Associates   (United States)

^b Oncology Hematology Care   (United States)

Author keywords

Acyclovir; Herpes; Herpes simplex virus; Mucositis; Valacyclovir

Indexed keywords

ACICLOVIR; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MELPHALAN; MITOXANTRONE; THIOTEPA; VALACICLOVIR;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW RESCUE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; FEMALE; HERPES SIMPLEX VIRUS 1; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS REACTIVATION;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; BONE MARROW TRANSPLANTATION; FEMALE; HERPES SIMPLEX; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT SELECTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VALINE;

EID: 0037261909     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703817     Document Type: Article

References (27)

1. Gluckman E, Lotsberg J, Devergie A et al. Oral acyclovir prophylactic treatment of herpes simplex infection after bone marrow transplantation. J Antimicrob Chemother 1983; 12(Suppl. B): 161-167.
2. Schubert MM, Peterson DE, Flournoy N et al. Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990; 70: 286-293.
3. Redding SW. Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr 1990; 9: 103-105.
4. Heimdahl A, Mattsson T, Dahllof G et al. The oral cavity as a port of entry for early infections in patients treated with bone marrow transplantation. Oral Surg Oral Med Oral Pathol 1989; 68: 711-716.
5. Lundgren G, Wilczek H, Lonnqvist B et al. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis Suppl 1985; 47: 137-144.
6. Hann IM, Prentice HG, Blacklock HA et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983; 287: 384-388.
7. Shepp DH, Newton BA, Dandliker PS et al. Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Ann Intern Med 1985; 102: 783-785.
8. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989; 59: 434-438.
9. Wade JC, Newton B, Flournoy N et al. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984; 100: 823-828.
10. Darby G. Acyclovir - and beyond. J Int Med Res 1994; 22 (Suppl. 1): 33A-42A.
11. Rayani SA, Nimmo CJ, Frighetto L et al. Implementation and evaluation of a standardized herpes simplex virus prophylaxis protocol on a leukemia/bone marrow transplant unit. Ann Pharmacother 1994; 28: 852-856.
12. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995; 28: 281-290.
13. Acosta EP, Fletcher CV. Valacyclovir. Ann Pharmacother 1997; 31: 185-191.
14. Fife KH, Barbarash RA, Rudolph T et al. Valacyclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valacyclovir International Herpes Simplex Virus Study Group. Sex Transm Dis 1997; 24: 481-486.
15. Eisen D, Essell J, Broun ER. Oral cavity complications of bone marrow transplantation. Semin Cutan Med Surg 1997; 16: 265-272.
16. Woo SB, Sonis ST, Sonis AL. The role of herpes simplex virus in the development of oral mucositis in bone marrow transplant recipients. Cancer 1990; 66: 2375-2379.
17. Saral R, Burns WH, Laskin OL et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63-67.
18. Shepp DH, Dandliker PS, Flournoy N et al. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. J Antimicrob Chemother 1985; 16: 385-389.
19. Lowance D, Hans-HN, Legendre C et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999; 340: 1462-1470.
20. Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994; 10: 281-291.
21. Gold J. The Albion Street Centre database, Sydney, Australia. J Acquir Immune Defic Syndrome Hum Retrovirol 1998; 17(Suppl. 1): S34-S37.
22. Sutor GC, Schmidt RE, Albrecht H. Thrombotic microangiopathies and HIV infection: report of two typical cases, features, of HUS and TTP, and review of the literature. Infection 1999; 27: 12-15.
23. Schimpff SC, Scott DA, Wade JC. Infections in cancer patients: some controversial issues. Support Care Cancer 1994; 2: 94-104 (see comments).
24. Sinnige LG, van der Meer JW et al. Is acyclovir prophylaxis necessary after bone marrow transplantation? Infection 1986; 14: 122-124.
25. Winston DJ, Ho WG, Gale RP et al. Prophylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol 1988; 24(Suppl. 1): S15-S23.
26. Englund JA, Zimmerman ME, Swierkosz EM et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990; 112: 416-422.
27. Darville JM, Ley BE, Roome AP et al. Acyclovir-resistant herpes simplex virus infections in a bone marrow transplant population. Bone Marrow Transplant 1998; 22: 587-589.